louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT02073370: Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics
Official title: Clinical Evaluation, Biomarkers and Metabolomics of Sarcopenia in Frail Older Adults at Ambulatory Clinics
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Frailty
Sarcopenia
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
Collaborators: name: National Health Research Institutes, Taiwan
name: National Taiwan University
First posted: 2014-02-27
Enrollment: 350
Sex: ALL
Minimum age (years): 65
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Healthy subjects One thousand Taiwanese subjects aged 20-40 will be recruited equally divided in both genders. Exclusion criteria includes (1) morbid obesity (BMI over 35) ; (2) long term use of body composition modified medications, like steroid, medications for endocrine diseases (hyperthyroidism, diabetes) and autoimmune diseases; (3) energy consumption diseases, such as cancer, organ failure; (4) pregnant women.

Patient enrollment The research subjects will be culled from outpatients aged over 65 at NTUH.

Brief summary: Sarcopenia related mobility dysfunction was a preventable presentation in transitional variation of frailty. However, the definition, associated risk factors, clinical course and outcome of sarcopenia in Taiwanese older adults are still under-clarified and need for further study.


Eligibility criteria: Inclusion Criteria:

* functional decline in recent one year
* cognitive impairment
* depressive symptom
* mobility impairment
* fall in recent one year
* eating or feeding problems
* weight loss
* co-morbid conditions≧5
* tracking by different physician ≧3 in recent half year
* poly-pharmacy≧8 in recent 3 months
* hospitalization ≧1 in recent one year
* emergency visits≧2 in recent one year
* aged ≧ 80.

Exclusion Criteria:

* non-ambulatory (bed-ridden) patients
* long-term residents at nursing homes
* patients with a life expectancy shorter than six months
* impairment in vision, hearing, or communicative ability, making convenience of clinical evaluation during the study period impossible.

Primary outcomes:
measure: Domestic operation tool of sarcopenia for older adults
timeFrame: Baseline
Secondary outcomes:
measure: Change from baseline in body composition during aging
timeFrame: up to 2 years
Other outcomes:
measure: Compare metabolomics profiles in sarcopenic older adults and non-sarcopenic older adults
timeFrame: up to 2 years
measure: The prognosis of sarcopenia in the older adults
timeFrame: up to 2 years
Locations:
city: Taipei
country: Taiwan
facility: National Taiwan University Hospital
Study officials:
affiliation: National Tiwan University, College of Medicine
name: Ching-Yu Chen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02553070: Health Professions Students and Faculty Perceptions of Poisoning Severity
Official title: Health Professions Students and Facutly Perceptions of Poisoning Severity
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Poisoning
Lead sponsor: University of Florida
Sponsor class: OTHER
First posted: 2015-09-17
Enrollment: 1000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Pharmacy students in their 1st or 2nd year of pharmacy school.

Brief summary: Inaccurate perceptions of the severity of an exposure may result in unnecessary visits to the Emergency Department or Health Care Facility which can result in crowding of Emergency Departments, unnecessary utilization of valuable health care resources, unnecessary treatments, and or mistakes / errors resulting in harm to the patient.

Inaccurate perceptions about the severity of an exposure can result in delays in proper evaluation and treatment resulting in harm or in some cases death of the patient.

Detailed description: Consumers and health professionals are often surprised about the toxicity (or lack of toxicity) after exposure to a number of pharmaceutical or non-pharmaceutical agents. Past experience with the survey used in this study has indicated that consumers and health professional perform about the same. Most individuals answer less than 50% of questions incorrectly.

Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (f/m). The survey will be given after a scheduled examination or other classroom activity and will not involve class time. Students will be provided a link to an online version of the survey.

Conclusions will be derived through the analysis of the data. At a later date, all students in the class (whether they participated in the survey or not)students will be provided a link to video that describes the correct answers to each of the cases and an explanation.

Eligibility criteria: Inclusion Criteria:

* All pharmacy students who agree to participate

Exclusion Criteria:

* None

Primary outcomes:
measure: Survey will be used for perceptions of poisoning severity
timeFrame: Day 1
Secondary outcomes:
Other outcomes:
Locations:
city: Gainesville
country: United States
facility: University of Florida College of Pharmacy
state: Florida
Study officials:
affiliation: University of Florida
name: Sven A Normann, PharmD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02633670: Hemopatch Versus No Hemopatch (Renal Transplant)
Official title: A Prospective Randomized Trial of Hemopatch Versus No Hemopatch For the Intraoperative Hemostasis During Deceased Donor Renal Transplant
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Renal Failure
Lead sponsor: St. Joseph's Healthcare Hamilton
Sponsor class: OTHER
First posted: 2015-12-17
Enrollment: 20
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: FACTORIAL
Primary purpose: TREATMENT

Brief summary: Kidney transplantation remains one of the most common organ transplanted today but the surgical technique has changed very little from the original pelvic operation. The deceased donor renal transplant poses a particular challenge to the surgeon due to lack of detailed pre operative vascular assessment. The hemopatch is a promising new sealing synthetic hemostatIc agent with a novel dual mechanism of action that is more convenient to apply rather then using other hemostatic agents, which require warming and/or mixing.


Eligibility criteria: Inclusion Criteria:

* Patients at least 18 years of age and capable of giving informed consent
* Patients scheduled for deceased donor renal transplant surgery

Exclusion Criteria:

* Patient undergoing live related transplant surgery.
* Patient having uncorrectable bleeding diathesis.
* Any patient in the no hemopatch group requiring additional haemostatic agents for achieving hemostasis like fibrillar or surgical.

Primary outcomes:
measure: Blood Loss
timeFrame: Baseline (Intraoperatively)
Secondary outcomes:
measure: Hemostasis achievement
timeFrame: Baseline (Intraoperatively)
measure: Drop in Hemoglobin
timeFrame: up to 48 hours postoperatively
measure: Amount of Perigraft Collection
timeFrame: up to 48 hours postoperative
Other outcomes:
Locations:
city: Hamilton
country: Canada
facility: Marylrose Gundayao
state: Ontario
Study officials:
affiliation: McMaster University
name: Anil Kapoor, MD, FRCSC
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03781570: Brain and Genetic Predictors of Individual Differences in Pain and Analgesia
Official title: Brain and Genetic Predictors of Individual Differences in Pain and Analgesia
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Pain, Acute
Lead sponsor: Trustees of Dartmouth College
Sponsor class: OTHER
Collaborators: name: QIMR Berghofer Medical Research Institute
First posted: 2018-12-20
Enrollment: 541
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The CTS includes 727 same-sex twin pairs between 26-38 years old (as of Spring 2017), originally derived from the Colorado Twin Registry, a population based registry, housed at the Institute for Behavioral Genetics (IBG) at the University of Colorado since 1984, with three previous waves of data collection (1997-2002, 2002-2008, and 2009-2014).

Brief summary: The purpose of the study is to gain a better understanding of pain processing in the brain. Our understanding of how pain is processed in the brain is limited. We are testing for individual differences in pain perception and emotion.


Eligibility criteria: Inclusion Criteria:

* Participants must be registered in the Colorado Community Twin Sample (CTS).

Exclusion Criteria:

* Not being registered in the Colorado Community Twin Sample (CTS).
* Any MRI contraindications.

Primary outcomes:
measure: Pain Rating Scores Made on a Visual Analog Scale (VAS)
timeFrame: Measured during pain tasks at a single 4 hour experimental session (within one month of screening completion).
Secondary outcomes:
Other outcomes:
Locations:
city: Boulder
country: United States
facility: University of Colorado, Boulder
state: Colorado
Study officials:
affiliation: University of Colorado, Boulder
name: Tor Wager, PHD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02048670: Pilot Project on External Vestibular Prosthesis in Chronic Subjective Dizziness
Official title: A Pilot Project to Investigate the Use of an External Vestibular Prosthesis Potential to Improve Clinical Management of Chronic Subjective Dizziness (CSD)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dizziness Chronic
Keywords: Pilot study
Assessment of sway phase
Therapy trial phase
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2014-01-29
Enrollment: 12
Sex: ALL
Minimum age (years): 25
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Researchers are gathering information on the safety and effectiveness of a new device called the BalanceBelt.

Detailed description: Ten consecutive subjects, ages 25-70 years, diagnosed with Chronic Subjective Dizziness (CDS) and ten healthy age and gender matched subjects will be asked to perform tests involving walking and balance while wearing the BalanceBelt. The BalanceBelt is a lightweight belt that will be worn under the clothes around the subjects waist and uses sensitive motion detectors and vibrates against the skin at four locations to provide information about posture and motion.

Eligibility criteria: Subject population: 20 patients with diagnosis of Chronic Subjective Dizziness (CSD) and 10 normal volunteers.

Inclusion Criteria:

* Subjects will be 25-70 years of age inclusive and pregnant women may participate.
* Patients will have CSD as their primary diagnosis for the cause of their balance and dizziness complaints provided by the Behavioral Medicine Program for Dizziness, a division of the Department of Psychiatry \& Psychology.
* Normal volunteers will have a negative history of otologic \& neurologic disorders and no history of dizziness and balance problems.
* Normal volunteers will have normal findings on a screening office examination for peripheral and central vestibular system involvement (see methods for details of the examination) and screening for normal or symmetrical hearing loss of explainable origin.

Exclusion Criteria:

* Patients with positive indications from testing of peripheral and/or central vestibular system involvement that is felt to be influencing the symptoms reported beyond the CSD alone.
* Patients with mobility restriction that would prevent participating in the tests or the intensive therapy trials.
* Subjects with hearing impairment that interferes with oral communication.

Primary outcomes:
measure: Degrees of Sway
timeFrame: baseline
Secondary outcomes:
measure: Visual Analog Scales Score
timeFrame: baseline
Other outcomes:
Locations:
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
Study officials:
affiliation: Mayo Clinic
name: Jeffrey Staab, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01224470: The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate
Official title: The Effects of Intravenous Dexmedetomidine on Spinal Anesthesia Using Low Dose Diluted Bupivacaine for Transurethral Resection of Prostate
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Transurethral Prostatectomy
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2010-10-20
Enrollment: 51
Sex: MALE
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL

Brief summary: Dexmedetomidine is a new selective and potent alpha-2 agonist. It has centrally acting anesthetic properties. It has been known that intrathecal addition of alpha-2 adrenergic agents result in prolongation of the duration of the sensory and motor blockade induced by hyperbaric bupivacaine. But the effects of intravenous dexmedetomidine on the spinal block was not evaluated. The aim of study is to assess the effect of intravenous dexmedetomidine on the low-dose spinal anesthesia for the transurethral surgery.


Eligibility criteria: Inclusion Criteria:

* ASA class I or II
* Elective transurethral prostatectomy
* aged \> 20

Exclusion Criteria:

* Coagulation deficiency
* infection on the back
* Congestive heart failure or arrythmia
* Chronic alcoholic disease
* Antidepressants therapy

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Severance Hospital
Study officials:
References:
citation: Hong JY, Kim WO, Yoon Y, Choi Y, Kim SH, Kil HK. Effects of intravenous dexmedetomidine on low-dose bupivacaine spinal anaesthesia in elderly patients. Acta Anaesthesiol Scand. 2012 Mar;56(3):382-7. doi: 10.1111/j.1399-6576.2011.02614.x. Epub 2012 Jan 4.
Clinical trial NCT05410470: Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis
Official title: Efficacy and Safety of Ruxolitinib in Patients With Myelofibrosis: A Retrospective Multicenter Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Myelofibrosis
Lead sponsor: Qilu Hospital of Shandong University
Sponsor class: OTHER
First posted: 2022-06-08
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: MF patients including primary and secondary MF patients who received ruxolitinib treatment are going to be recruited.

Brief summary: Ruxolitinib is a Janus kinase (JAK) 1/2 inhibitor currently used in the treatment of Myelofibrosis (MF). Ruxolitinib confirmed improvements in splenomegaly, MF-related symptoms and survival benefit in COMFORT and JUMP studies. At present, the real-world data on the efficacy and safety of ruxolitinib in the treatment of MF in China is still insufficient. The aim of this study was to evaluate the efficacy and safety of ruxolitinib in patients with MF and to provide guidance for the usage of ruxolitinib in MF in China.This was a retrospective, multicenter study of MF patients who received ruxolitinib treatment in Shandong province from August 2012 to December 2021. Data were analyzed using SPSS. Overall survival (OS) and Event-free survival (EFS) were estimated using the Kaplan- Meier method.


Eligibility criteria: Inclusion Criteria:

1. Male or female patients aged ≥18 years with a diagnosis of primary or secondary MF by World Health Organization and International Working Group for Myeloproliferative Neoplasms Research and Treat- ment (IWG-MRT) criteria;
2. Received ruxolitinib treatment for ≥3 months.

Exclusion Criteria:

1. Malignant tumors with other progression or myelofibrosis secondary to other diseases;
2. Exclude myelofibrosis patients after splenectomy;
3. Patients with poor compliance with case follow-up or lost to follow-up.

Primary outcomes:
measure: The proportion of patients with a ≥35% reduction in palpable spleen volume from baseline.
timeFrame: From Week 0 through Week 24
Secondary outcomes:
measure: The proportion of patients with ≥50% reduction in Total Symptom Score (TSS) from baseline.
timeFrame: From Week 0 through Week 24
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03686670: Acceptability Study by Patients Admitted for Suicide and by Medical Staff for Clinical Data Collection Through an E-health Platform
Official title: Acceptability Study SMARTphone to Collect Clinical Data Using the Memind App by Patients and Medical Satff.
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Suicide, Attempted
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2018-09-27
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: After agreeing to participate, clinician will collect the non-opposition for each patient. Patient with a current suicidal behavior disorder (according to DSM-5), i.e. having attempted suicide in the current year, will be test the application.

Brief summary: The study goal is to determine the feasbility and interest of monitoring mental health and non mental health related simptoms in Outpatients in order to prevent suicide.

Detailed description: Taking into account the strengths and pitfalls of existing suicide risk assessment methods, we have designed a system capable to combine EMA and continuous monitoring of patients using the smartphone's and/or wearable's sensors and data entry in order to monitor and predict suicide risk. For example, both poor sleep quality and disturbed appetite are clinical markers of depression, with a bidirectional relationship. Their changes could precede the increase of suicidal behavior as sleep and appetite are both influenced by mood state and regulated by the serotonergic system. Our hypothesis is that tracking mental health simptoms regularly through self-report could serve as a consistent and non-biased shortcut to assess mood state, its biological underpinnings and could potentially predict suicidal behavior.

Eligibility criteria: To be eligible for the study, patients must be 18 years or older, attend an outpatient clinic or emergency departments of participating clinical services and owning an android or IOS smartphone

Primary outcomes:
measure: Evaluate the feasibility of this intensive data capture technology in patients in real world without economical incentives.
timeFrame: 2 month
Secondary outcomes:
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
affiliation: CHRU de Brest
name: Sofian BERROUIGUET
role: STUDY_DIRECTOR
References:
Clinical trial NCT00469170: A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method
Official title: A Safety and Acceptability Study of a Vaginal Ring Microbicide Delivery Method for the Prevention of HIV Infection in Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: EARLY_PHASE1
Conditions: HIV Infections
Keywords: HIV-1
HIV seronegativity
Lead sponsor: International Partnership for Microbicides, Inc.
Sponsor class: INDUSTRY
First posted: 2007-05-04
Enrollment: 220
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: The proposed study is a multi-centre, open-label crossover study to assess the safety and acceptability of a silicone elastomer vaginal ring (containing no drug) when inserted for a 12 week period in 200 healthy, sexually active women.


Eligibility criteria: Inclusion Criteria:

* Female, age 18-35 years
* Willing and able to provide written informed consent
* HIV-uninfected and otherwise healthy
* Self-reported sexually active
* On a stable hormonal contraceptive regimen
* Regular menstrual cycle
* Willing to refrain from use of vaginal products or objects during the study

Exclusion Criteria:

* Currently pregnant or last pregnancy within 3 months prior to enrollment
* Currently breast-feeding
* Participated in any other research study within 30 days prior to enrollment;
* Symptomatic untreated vaginal infections within 2 weeks prior to enrollment
* Presence of abnormal physical finding on the vulva, vaginal walls or cervix
* History of significant urogenital or uterine prolapse, undiagnosed vaginal bleeding, urethral obstruction;
* Pap smear result at screening that requires cryotherapy, biopsy, treatment (other than for infection), or further evaluation
* Unexplained, undiagnosed abnormal bleeding per vagina, bleeding per vagina during or following vaginal intercourse, or gynecologic surgery within 90 days prior to enrollment
* Any serious acute, chronic or progressive disease

Primary outcomes:
measure: The primary measure of acceptability will be defined as the proportion of women indicating that they would use the study product if it is found to prevent HIV.
timeFrame: 3 months
measure: The primary measure of safety will be the proportion of women who have abnormal observations during the pelvic/speculum examinations and the proportion of women who experience adverse events
timeFrame: 3 months
Secondary outcomes:
Other outcomes:
Locations:
city: Yeoville
country: South Africa
facility: Reproductive Health & HIV Research Unit - Sheshisani IPM Clinic
state: Johannesburg
city: Durban
country: South Africa
facility: South African Medical Research Council
state: KwaZulu Natal
city: Cape Town
country: South Africa
facility: Desmond Tutu HIV Foundation, Masiphumelele
city: Moshi
country: Tanzania
facility: Kilimanjaro Reproductive Health Program
Study officials:
affiliation: IPM
name: Dr. Annalene Nel
role: STUDY_DIRECTOR
References: